Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma files new $200 million at-the-market share sale program with Jefferies

Neutral Impact 2 of 5 financing

Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.

Key points

  • New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
  • Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
  • Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
  • Ropes & Gray LLP legal opinion filed as Exhibit 5.1

The filing

CompanyZenas BioPharma, Inc. (ZBIO)
Form8-K, current report
Filed with the SECNov 6, 2026, 4:16 PM ET
Accession number0001104659-26-123885

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.